IDH-mutant glioma
Oncology · 2025–2026
2decisions
1medicine
2carried consumer input
881individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| vorasidenib Treatment of patients with isocitrate dehydrogenase (IDH)-mutant astrocytoma or oligodendroglioma who have residual or recurrent disease after at least one… | Mar 2026 | Recommended with restriction | 774 individuals Rare Cancers Australia · Brain Tumour Alliance Australia · Cure Brain Cancer Foundation · Mind Foundation |
| vorasidenib Treatment of patients with WHO Grade 2 IDH-mutant astrocytoma or oligodendroglioma who have residual or recurrent disease after at least one prior surgery and… | Jul 2025 | Not recommended | 107 individuals Rare Cancers Australia · Cure Brain Cancer Foundation · Brain Tumour Alliance Australia · Cooperative Trial Group · Medical Oncology Group |
Who spoke
Rare Cancers Australia · Cure Brain Cancer Foundation · Brain Tumour Alliance Australia · Cooperative Trial Group · Medical Oncology Group · Mind Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.